登录 | 注册    关注公众号  
微信公众号
搜索
 > 【SIGIRR】

SIGIRR信息

英文名称:Toll like receptor 4
中文名称:Toll样受体4
靶点别称:EC:3.2.2.6,TLR4,Toll Like Receptor 4,Toll-Like Receptor 4,HToll,Homolog Of Drosophila Toll,CD284 Antigen,ARMD10,CD284,TLR-4,TOLL,Toll Like Receptor 4 Protein
上市药物数量:1
临床药物数量:14
最高研发阶段:批准上市

SIGIRR产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
SIR-H5255
Human
Human SIGIRR Protein, Fc Tag (MALS verified)
ACRO质量管理体系
 
评论(0)
 

SIGIRR 分子别名

Single Ig IL-1-related receptor,Single Ig IL-1R-related molecule,Single immunoglobulin domain-containing IL1R-related protein,Toll/interleukin-1 receptor 8,TIR8

SIGIRR 分子背景

Single immunoglobulin IL-1-related receptor (SIGIRR), which is also known as Toll/interleukin-1 receptor 8, is a member of the interleukin-1 receptor (IL-1R) family. SIGIRR acts as a negative regulator of the Toll-like and IL-1R receptor signaling pathways. Attenuates the recruitment of receptor-proximal signaling components to the TLR4 receptor, probably through an TIR-TIR domain interaction with TLR4. Through its extracellular domain interferes with the heterodimerization of Il1R1 and IL1RAP.

SIGIRR 前沿进展

PRMT5 highly expressed on CD16 + CD56- natural killer cells is correlated with NK cells exhaustion in colorectal cancer mesenchyme
Nie, Chang, Yang et al
Cancer Immunol Immunother (2025) 74 (4), 139
Abstract: To investigate the relationships between changes in the phenotype of natural killer cells (NK cells) in the microenvironment of colorectal cancer (CRC) and the expression of important immune checkpoints. To assess the expression level of CD16 bright CD56 negative (CD16 + CD56-) NK cell-associated immune checkpoints, including protein arginine methyltransferase 5 (PRMT5) and T-cell immunoreceptor with Ig and ITIM domains (TIGIT), single-immunoglobulin interleukin-1-related receptor (SIGIRR), in CRC mesenchyme.A total of 194 patients who were diagnosed with CRC were screened. The percentage of NK cells and the expression levels of their surface receptors, including PRMT5, CD56, CD69, TIGIT, CD16, IFN-γ, and SIGIRR, in the tumor microenvironment (TME) of CRC were assessed. Immunohistochemical staining, multiplex immunohistochemistry, and single-cell sequencing were performed.Compared with normal mesenchyme, NK cells were less in CRC mesenchyme. The percentage of CD16 + CD56- NK cells in tumor mesenchyme was significantly higher, the number of CD16 + NK cells was more, and the number of CD56 + NK cells was less in CRC mesenchyme. High expression of TIGIT and PRMT5 expression affected the progression of CRC. The expression of PRMT5 and SIGIRR expression was significantly increased in CD16 + CD56- NK cells, and both genes were identified as important morbidity factors. PRMT5 and SIGIRR may contribute to the phenotype changes of NK cells in CRC.The microenvironment of CRC is in an immunosuppressive state characterized mainly by high expression of TIGIT, CD16, PRMT5, and SIGIRR; low expression of CD56, IFN-γ, and CD69; significantly decreased percentage of CD56 + NK cells; and significantly increased percentage of CD16 + CD56- NK cells with weakened killing ability. PRMT5 and TIGIT may be closely related to the formation of CD16 + CD56- NK cells with weakened killing ability.© 2025. The Author(s).
AAV9-delivery of interleukin-37b gene prevents recurrent herpetic stromal keratitis via the SIGIRR pathway in mice
Wu, Liu, Wang et al
J Control Release (2025) 381, 113600
Abstract: Ocular herpes simplex virus type I (HSV-1) infection can lead to herpes stromal keratitis (HSK), a condition that may recur throughout a person's life and often results in progressive corneal scarring, which ultimately causes visual impairment. Since existing antiviral agents are ineffective against recurrent HSK, we aimed to explore a strategy to prevent or control recurrent HSK. Adeno-associated virus (AAV) delivery system can transduce target genes into corneal epithelial cells and establish long-term stable gene expression, and providing a promising approach for the prevention and management of recurrent HSK. In this study, interleukin-37 (IL-37), an anti-inflammatory factor, is identified as a therapeutic agent for recurrent HSK via the SIGIRR pathway. AAV9-IL-37bΔ1-45 gene therapy prevents recurrent HSK in HSV-1 latently infected mice and alleviates corneal injury in mice with HSK. In conclusion, our present study establishes a strong foundation for the prevention of recurrent HSK through AAV9-IL-37bΔ1-45 gene therapy.Copyright © 2024. Published by Elsevier B.V.
Age-Related Integrative Transcriptomic Profiling of Human Granulosa Cells Reveals mRNA-microRNA Regulatory Network Associated with Key Ovulation Dynamics
Rogers, Gad, Cork et al
Biol Reprod (2025)
Abstract: Advanced maternal age (AMA) patients experience decreased success from assisted reproductive technologies (ART), attributed to the quantity and quality of oocytes, which is significantly influenced by the intrafollicular granulosa cells (GCs). In this study, we compared the mRNA and microRNA (miRNA) transcriptomes between young (< 32 y.o.) and AMA (> 38 y.o.) patients' GCs to identify potential ovarian aging-related molecular signatures. We identified 293 and 21 differentially expressed genes (DEGs) and miRNAs (DE miRNAs), respectively, between young and aged GCs. Highly expressed mitochondrial-encoded genes, MT-ND3, MT-ND6, and MT-CYB, were downregulated in aged GCs, indicating potential mitochondrial insufficiency. Additionally, pathway analysis indicates DEGs are involved in inflammation, cytokine signaling, extracellular matrix (ECM) remodeling, and angiogenesis. Key DEGs related to these processes include CXCL8, IL1B, NLRP3, SIGIRR, ANGPT2, ADAM8, and ADAMTS14. Additionally, target gene prediction and pathway analysis of DE miRNAs indicates their potential post-transcriptional regulation of genes associated with cell signaling, mitochondrial function, oxidative stress, apoptosis, and senescence pathways in addition to cytokine signaling, angiogenesis, and ECM remodeling. To investigate regulatory mechanisms further, we looked at the DEGs' convergence with the DE miRNAs predicted target genes and we identified miR-483-3p, miR-1268a, miR-4497, miR-7704, miR-135a-5p, miR-1261, and miR-4791 as potential crucial regulators of genes involved in pathways associated with inflammation, ECM, and angiogenesis. This data suggests that aged GCs have an impaired ability to elicit the same pro-inflammatory response combined with dysregulation of angiogenesis and ECM remodeling compared to young GCs, and miRNA may play a role in regulating key ovulatory processes. While this study identifies potential regulatory relationships between DE miRNAs and DEGs, experimental validation is necessary to confirm the relationships and biological relevance.© The Author(s) 2025. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Showing 1-3 of 232 papers.
Powered by BizGenius

SIGIRR上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Ibudilast 异丁司特 AV-411; KC-404; MN-166 批准上市 Ketas, Pinatos, Eyevinal Japan 哮喘, 多发性硬化, 神经痛 Kyorin Pharmaceutical Co Ltd 物质相关性障碍, HIV感染, 阿片类依赖, 继发性头痛症, 糖尿病神经病变, 多发性硬化, 慢性进行性多发性硬化, 病毒性肺炎, 酗酒, 哮喘, 神经痛, 肌萎缩性侧索硬化 详情

SIGIRR临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Mosedipimod EC-18 临床二期 Enzychem Lifesciences Co 中性粒细胞减少, 新型冠状病毒感染, 口腔炎, 发热性中性粒细胞减少症, 特应性皮炎 详情
Paridiprubart EB-07; EB-05; NI-0101 临床二期 Novimmune Sa 新型冠状病毒感染, 肺纤维化, 成人呼吸窘迫综合征 详情
PEPA-10 PEPA-10 临床二期 Immunovo BV 肿瘤 详情
eNamptcumab ALT-100 临床二期 Aqualung Therapeutics Corp 呼吸机相关性肺损伤, 成人呼吸窘迫综合征, 肺纤维化, 前列腺癌, 肺动脉高压, 绒毛膜羊膜炎 详情
Glycopyranosyl lipid adjuvant (Immune Design) GLA; G100; GLA-SE; ID-G100; G-100 临床二期 Immune Design HIV感染, 皮肤黑色素瘤, 恶性疟, 肺结核, 肉瘤, 钩虫感染, 利什曼原虫感染, 血吸虫病 详情
Glycopyranosyl lipid adjuvant (Revelation Biosciences) PHAD (Revelation Biosciences); REVTx 99; REVTx-99a; REVTx-99b; REVTx-100 (Revelation Biosciences); REVTx-200 (Revelation Biosciences); REVTx-300 (Revelation Biosciences); GLA (Revelation Biosciences) 临床二期 Revelation Biosciences Inc 交叉感染, 甲型流感病毒感染, 急性肾损伤, 手术伤口感染, 慢性肾功能不全, 心肌炎 详情
TARA-002(Protara Therapeutics) TARA-002 临床二期 Protara Therapeutics Inc 膀胱癌, 淋巴管畸形 详情
ApTOLL 临床二期 aptaTargets SL 中风, 缺血性卒中 详情
Temelimab GNN-001; GENHP-01; GNbAC-1 临床二期 Geneuro Sa 复发-缓解型多发性硬化, 一型糖尿病, 多发性硬化, 新冠后遗症 详情
GSK-1795091 1795091; GSK-1795091; CRX-601 临床一期 葛兰素史克 肿瘤 详情
PET-lipid A 临床一期 Cascadian Therapeutics Inc 疫苗接种 详情
SAR-439794 SAR-439794 临床一期 赛诺菲 食物过敏 详情
INI-2004 INI-2004 临床一期 Inimmune Corp 呼吸道感染, 肿瘤, 食物过敏, 过敏性鼻炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定